Summary

HLA Typing for Transplant Market
The HLA typing for transplant market was valued at $0.9 billion in 2023 and is projected to reach $1.7 billion by 2033, growing at a CAGR of 6.6% from 2024 to 2033.
Human leukocyte antigen (HLA) typing for transplant is an analysis procedure that determines the compatibility between donor and recipient for organ transplant. The proteins transcribed by HLA genes play a critical role in the immune system of humans. The most common forms of organ transplants that involve HLA typing are stem cell and solid organ transplants. A high percentage of HLA matches is critical to ensure that donor or recipient cells do not attack the other post-transplantation.

Rise in the prevalence of chronic conditions such as liver cirrhosis and kidney diseases has fueled organ transplant procedures globally, driving the HLA typing for transplant market. In addition, the availability of effective reimbursement policies for HLA typing and organ transplantation has enhanced their accessibility for patients, augmenting the development of the market. An emerging trend poised to dominate the HLA typing for transplant market is the deployment of third-generation sequencing techniques such as single-molecule real-time sequencing and Oxford Nanopore. These techniques improve accuracy, reduce ambiguity, and enhance the assessment of compatibility for transplantation.

However, the high expenditure associated with HLA typing and organ transplantations deters several patients from opting for such treatments, restraining the development of the market. Moreover, the scarcity of available organs reduces the opportunities for transplantations, which impacts the overall demand for HLA typing and hampers the market growth. On the contrary, rise in awareness regarding the necessity of organ donation has upsurged the number of individuals signing up for it post their demise. For instance, a novel annual record was set in the U.S. in 2023 owing to the availability of more than 16,000 deceased organ donors. Therefore, rise in the number of readily available organs for transplant is projected to boost HLA typing for testing the compatibility, opening new avenues for the market.

Segment Review
The HLA typing for transplant market is segmented into technology, product, application, type, end user, and region. On the basis of technology, the market is bifurcated into molecular assay and non-molecular assay. Depending on product, it is divided into instruments, reagents & consumables, and software & services. According to application, it is bifurcated into diagnostic and research. As per type, it is classified into organ transplant and tissue. By end user, it is categorized into independent reference laboratories, hospital & transplant center, and other. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings
On the basis of technology, the molecular assay segment held a high share of the market in 2023.
Depending on product, the reagents & consumables segment acquired a high stake in the market in 2023.
According to application, the diagnostic segment dominated the market in 2023.
As per type, the organ transplant segment was the highest shareholder in 2023.
By end user, the independent reference laboratories segment accounted for a high share of the market in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The leading players operating in the global HLA typing for transplant market include Luminex Corporation, Pacific Biosciences of California, Inc., Abbott Laboratories, Bio-Rad Laboratories, BioReference Laboratories, Qiagen N.V, F. Hoffmann-La Roche Ltd., Illumina Inc., Fujirebio, and BAG Diagnostic GmbH. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Average Selling Price Analysis / Price Point Analysis
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By Technology
● Molecular Assay
● Non-Molecular Assay
By Product
● Instruments
● Reagents Consumables
● Software Services
By Application
● Diagnostic
● Research
By Type
● Organ Transplant
● Tissue
By End User
● Independent Reference Laboratories
● Hospital Transplant Center
● Other
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ Australia
○ India
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Luminex Corporation
○ Pacific Biosciences of California, Inc
○ Abbott Laboratories
○ Bio-Rad Laboratories
○ BioReference Laboratories
○ Qiagen N.V
○ F. Hoffmann-La Roche Ltd.
○ Illumina Inc.
○ Fujirebio
○ BAG Diagnostic GmbH

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology
4.2. Molecular Assay
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Non-Molecular Assay
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT
5.1. Market Overview
5.1.1 Market Size and Forecast, By Product
5.2. Instruments
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Reagents Consumables
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Software Services
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Application
6.2. Diagnostic
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Research
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
CHAPTER 7: HLA TYPING FOR TRANSPLANT MARKET, BY TYPE
7.1. Market Overview
7.1.1 Market Size and Forecast, By Type
7.2. Organ Transplant
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Tissue
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
CHAPTER 8: HLA TYPING FOR TRANSPLANT MARKET, BY END USER
8.1. Market Overview
8.1.1 Market Size and Forecast, By End User
8.2. Independent Reference Laboratories
8.2.1. Key Market Trends, Growth Factors and Opportunities
8.2.2. Market Size and Forecast, By Region
8.2.3. Market Share Analysis, By Country
8.3. Hospital Transplant Center
8.3.1. Key Market Trends, Growth Factors and Opportunities
8.3.2. Market Size and Forecast, By Region
8.3.3. Market Share Analysis, By Country
8.4. Other
8.4.1. Key Market Trends, Growth Factors and Opportunities
8.4.2. Market Size and Forecast, By Region
8.4.3. Market Share Analysis, By Country
CHAPTER 9: HLA TYPING FOR TRANSPLANT MARKET, BY REGION
9.1. Market Overview
9.1.1 Market Size and Forecast, By Region
9.2. North America
9.2.1. Key Market Trends and Opportunities
9.2.2. Market Size and Forecast, By Technology
9.2.3. Market Size and Forecast, By Product
9.2.4. Market Size and Forecast, By Application
9.2.5. Market Size and Forecast, By Type
9.2.6. Market Size and Forecast, By End User
9.2.7. Market Size and Forecast, By Country
9.2.8. U.S. HLA Typing for Transplant Market
9.2.8.1. Market Size and Forecast, By Technology
9.2.8.2. Market Size and Forecast, By Product
9.2.8.3. Market Size and Forecast, By Application
9.2.8.4. Market Size and Forecast, By Type
9.2.8.5. Market Size and Forecast, By End User
9.2.9. Canada HLA Typing for Transplant Market
9.2.9.1. Market Size and Forecast, By Technology
9.2.9.2. Market Size and Forecast, By Product
9.2.9.3. Market Size and Forecast, By Application
9.2.9.4. Market Size and Forecast, By Type
9.2.9.5. Market Size and Forecast, By End User
9.2.10. Mexico HLA Typing for Transplant Market
9.2.10.1. Market Size and Forecast, By Technology
9.2.10.2. Market Size and Forecast, By Product
9.2.10.3. Market Size and Forecast, By Application
9.2.10.4. Market Size and Forecast, By Type
9.2.10.5. Market Size and Forecast, By End User
9.3. Europe
9.3.1. Key Market Trends and Opportunities
9.3.2. Market Size and Forecast, By Technology
9.3.3. Market Size and Forecast, By Product
9.3.4. Market Size and Forecast, By Application
9.3.5. Market Size and Forecast, By Type
9.3.6. Market Size and Forecast, By End User
9.3.7. Market Size and Forecast, By Country
9.3.8. Germany HLA Typing for Transplant Market
9.3.8.1. Market Size and Forecast, By Technology
9.3.8.2. Market Size and Forecast, By Product
9.3.8.3. Market Size and Forecast, By Application
9.3.8.4. Market Size and Forecast, By Type
9.3.8.5. Market Size and Forecast, By End User
9.3.9. France HLA Typing for Transplant Market
9.3.9.1. Market Size and Forecast, By Technology
9.3.9.2. Market Size and Forecast, By Product
9.3.9.3. Market Size and Forecast, By Application
9.3.9.4. Market Size and Forecast, By Type
9.3.9.5. Market Size and Forecast, By End User
9.3.10. UK HLA Typing for Transplant Market
9.3.10.1. Market Size and Forecast, By Technology
9.3.10.2. Market Size and Forecast, By Product
9.3.10.3. Market Size and Forecast, By Application
9.3.10.4. Market Size and Forecast, By Type
9.3.10.5. Market Size and Forecast, By End User
9.3.11. Italy HLA Typing for Transplant Market
9.3.11.1. Market Size and Forecast, By Technology
9.3.11.2. Market Size and Forecast, By Product
9.3.11.3. Market Size and Forecast, By Application
9.3.11.4. Market Size and Forecast, By Type
9.3.11.5. Market Size and Forecast, By End User
9.3.12. Spain HLA Typing for Transplant Market
9.3.12.1. Market Size and Forecast, By Technology
9.3.12.2. Market Size and Forecast, By Product
9.3.12.3. Market Size and Forecast, By Application
9.3.12.4. Market Size and Forecast, By Type
9.3.12.5. Market Size and Forecast, By End User
9.3.13. Rest Of Europe HLA Typing for Transplant Market
9.3.13.1. Market Size and Forecast, By Technology
9.3.13.2. Market Size and Forecast, By Product
9.3.13.3. Market Size and Forecast, By Application
9.3.13.4. Market Size and Forecast, By Type
9.3.13.5. Market Size and Forecast, By End User
9.4. Asia-Pacific
9.4.1. Key Market Trends and Opportunities
9.4.2. Market Size and Forecast, By Technology
9.4.3. Market Size and Forecast, By Product
9.4.4. Market Size and Forecast, By Application
9.4.5. Market Size and Forecast, By Type
9.4.6. Market Size and Forecast, By End User
9.4.7. Market Size and Forecast, By Country
9.4.8. Japan HLA Typing for Transplant Market
9.4.8.1. Market Size and Forecast, By Technology
9.4.8.2. Market Size and Forecast, By Product
9.4.8.3. Market Size and Forecast, By Application
9.4.8.4. Market Size and Forecast, By Type
9.4.8.5. Market Size and Forecast, By End User
9.4.9. China HLA Typing for Transplant Market
9.4.9.1. Market Size and Forecast, By Technology
9.4.9.2. Market Size and Forecast, By Product
9.4.9.3. Market Size and Forecast, By Application
9.4.9.4. Market Size and Forecast, By Type
9.4.9.5. Market Size and Forecast, By End User
9.4.10. Australia HLA Typing for Transplant Market
9.4.10.1. Market Size and Forecast, By Technology
9.4.10.2. Market Size and Forecast, By Product
9.4.10.3. Market Size and Forecast, By Application
9.4.10.4. Market Size and Forecast, By Type
9.4.10.5. Market Size and Forecast, By End User
9.4.11. India HLA Typing for Transplant Market
9.4.11.1. Market Size and Forecast, By Technology
9.4.11.2. Market Size and Forecast, By Product
9.4.11.3. Market Size and Forecast, By Application
9.4.11.4. Market Size and Forecast, By Type
9.4.11.5. Market Size and Forecast, By End User
9.4.12. South Korea HLA Typing for Transplant Market
9.4.12.1. Market Size and Forecast, By Technology
9.4.12.2. Market Size and Forecast, By Product
9.4.12.3. Market Size and Forecast, By Application
9.4.12.4. Market Size and Forecast, By Type
9.4.12.5. Market Size and Forecast, By End User
9.4.13. Rest of Asia-Pacific HLA Typing for Transplant Market
9.4.13.1. Market Size and Forecast, By Technology
9.4.13.2. Market Size and Forecast, By Product
9.4.13.3. Market Size and Forecast, By Application
9.4.13.4. Market Size and Forecast, By Type
9.4.13.5. Market Size and Forecast, By End User
9.5. LAMEA
9.5.1. Key Market Trends and Opportunities
9.5.2. Market Size and Forecast, By Technology
9.5.3. Market Size and Forecast, By Product
9.5.4. Market Size and Forecast, By Application
9.5.5. Market Size and Forecast, By Type
9.5.6. Market Size and Forecast, By End User
9.5.7. Market Size and Forecast, By Country
9.5.8. Brazil HLA Typing for Transplant Market
9.5.8.1. Market Size and Forecast, By Technology
9.5.8.2. Market Size and Forecast, By Product
9.5.8.3. Market Size and Forecast, By Application
9.5.8.4. Market Size and Forecast, By Type
9.5.8.5. Market Size and Forecast, By End User
9.5.9. Saudi Arabia HLA Typing for Transplant Market
9.5.9.1. Market Size and Forecast, By Technology
9.5.9.2. Market Size and Forecast, By Product
9.5.9.3. Market Size and Forecast, By Application
9.5.9.4. Market Size and Forecast, By Type
9.5.9.5. Market Size and Forecast, By End User
9.5.10. South Africa HLA Typing for Transplant Market
9.5.10.1. Market Size and Forecast, By Technology
9.5.10.2. Market Size and Forecast, By Product
9.5.10.3. Market Size and Forecast, By Application
9.5.10.4. Market Size and Forecast, By Type
9.5.10.5. Market Size and Forecast, By End User
9.5.11. Rest of LAMEA HLA Typing for Transplant Market
9.5.11.1. Market Size and Forecast, By Technology
9.5.11.2. Market Size and Forecast, By Product
9.5.11.3. Market Size and Forecast, By Application
9.5.11.4. Market Size and Forecast, By Type
9.5.11.5. Market Size and Forecast, By End User
CHAPTER 10: COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Top Winning Strategies
10.3. Product Mapping Of Top 10 Player
10.4. Competitive Dashboard
10.5. Competitive Heatmap
10.6. Top Player Positioning, 2023
CHAPTER 11: COMPANY PROFILES
11.1. Luminex Corporation
11.1.1. Company Overview
11.1.2. Key Executives
11.1.3. Company Snapshot
11.1.4. Operating Business Segments
11.1.5. Product Portfolio
11.1.6. Business Performance
11.1.7. Key Strategic Moves and Developments
11.2. Pacific Biosciences Of California, Inc
11.2.1. Company Overview
11.2.2. Key Executives
11.2.3. Company Snapshot
11.2.4. Operating Business Segments
11.2.5. Product Portfolio
11.2.6. Business Performance
11.2.7. Key Strategic Moves and Developments
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Key Executives
11.3.3. Company Snapshot
11.3.4. Operating Business Segments
11.3.5. Product Portfolio
11.3.6. Business Performance
11.3.7. Key Strategic Moves and Developments
11.4. Bio-Rad Laboratories
11.4.1. Company Overview
11.4.2. Key Executives
11.4.3. Company Snapshot
11.4.4. Operating Business Segments
11.4.5. Product Portfolio
11.4.6. Business Performance
11.4.7. Key Strategic Moves and Developments
11.5. BioReference Laboratories
11.5.1. Company Overview
11.5.2. Key Executives
11.5.3. Company Snapshot
11.5.4. Operating Business Segments
11.5.5. Product Portfolio
11.5.6. Business Performance
11.5.7. Key Strategic Moves and Developments
11.6. Qiagen N.V
11.6.1. Company Overview
11.6.2. Key Executives
11.6.3. Company Snapshot
11.6.4. Operating Business Segments
11.6.5. Product Portfolio
11.6.6. Business Performance
11.6.7. Key Strategic Moves and Developments
11.7. F. Hoffmann-La Roche Ltd.
11.7.1. Company Overview
11.7.2. Key Executives
11.7.3. Company Snapshot
11.7.4. Operating Business Segments
11.7.5. Product Portfolio
11.7.6. Business Performance
11.7.7. Key Strategic Moves and Developments
11.8. Illumina Inc.
11.8.1. Company Overview
11.8.2. Key Executives
11.8.3. Company Snapshot
11.8.4. Operating Business Segments
11.8.5. Product Portfolio
11.8.6. Business Performance
11.8.7. Key Strategic Moves and Developments
11.9. Fujirebio
11.9.1. Company Overview
11.9.2. Key Executives
11.9.3. Company Snapshot
11.9.4. Operating Business Segments
11.9.5. Product Portfolio
11.9.6. Business Performance
11.9.7. Key Strategic Moves and Developments
11.10. BAG Diagnostic GmbH
11.10.1. Company Overview
11.10.2. Key Executives
11.10.3. Company Snapshot
11.10.4. Operating Business Segments
11.10.5. Product Portfolio
11.10.6. Business Performance
11.10.7. Key Strategic Moves and Developments